Thai national guidelines for the prevention of motherto- child transmission of HIV: March 2010

1. Department of Health. Guidelines of prevention of mother-to-child HIV transmission management and care for HIV-infected women and families. Department of Health, Ministry of Public Health, May 2007.Search in Google Scholar

2. McIntyre JA, Martinson N, Gray GE, for the Trial 1413 Investigator Team. Single dose nevirapine combined with a short course of combivir for prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and infant resistant virus. Antivir Ther. 2005; 10 (suppl 1): S4.Search in Google Scholar

3. Results of HIV Sero-surveillance, Thailand 1989-2008. Source: AIDS division, Bureau of Epidemiology, Department of Disease Control. Available at http://epid.moph.go.th/.Search in Google Scholar

4. Naiwatanakul T, Punsuwan N, Kullerk N, Faikratok W, Lolekha R, Sangwanloy O, et al. Reduction in HIV transmission risk following recommendations for CD4 testing to guide selection of prevention of mother-tochild (PMTCT) regimens, Thailand, 2006-2007. Presented at 5th International AIDS Society Conference on HIV Pathogenesis and Treatment. Capetown, 19-22 July 2009 (Abstract CDC019).Search in Google Scholar

5. Health promotion project evaluation report in social and economic development agenda 9. (February 2007). Business printing office of veteran support organization publisher.Search in Google Scholar

6. Ad hoc reporting of Saiyairak family project. Department of Health. Available at http://www.saiyairakhospital.com/newdemo/admin/user_report.html, Accessed Dec 23, 09.Search in Google Scholar

7. Bureau of Health Promotion, Department of Health, Bureau of Epidemiology, Department of Disease Control, and Thailand MOPH-U.S. CDC collaboration. Presented at Meeting to report the National PMTCT Program Evaluation 2007, Bangkok, 2 February 2008.Search in Google Scholar

8. WHO. Rapid advice. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. November 2009. http://www.who.int/hiv/pub/mtct/advice/en/; Accessed 25 March, 2010.Search in Google Scholar

9. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004; 351:217-28.10.1056/NEJMoa03350015247338Search in Google Scholar

10. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-tochild transmission of HIV. AIDS. 2007; 21 (Suppl 4): S65-71.10.1097/01.aids.0000279708.09180.f517620755Search in Google Scholar

11. Health Intervention and Technology Assessment Program (HITAP). Cost benefit and feasibility study of HAART for prevention of mother-to-child HIV transmission in Thailand. Presented at Steering Group Committee of HIV/AIDS System Development, Bangkok, November, 2009.Search in Google Scholar

12. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005; 19:795-9.10.1097/01.aids.0000168973.59466.1415867493Open DOISearch in Google Scholar

13. Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007; 44:371-6.10.1097/QAI.0b013e318032bbee17259905Search in Google Scholar

14. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, et al. Safety of nevirapinecontaining antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006; 7: 338-44.10.1111/j.1468-1293.2006.00386.x16945080Search in Google Scholar

15. Kondo W, Carraro EA, Prandel E, Dias JM, Perini J, Macedo RL, et al. Nevirapine-induced side effects in pregnant women: experience of a Brazilian University Hospital. Braz J Infect Dis. 2007; 11:544-8.10.1590/S1413-8670200700060000418327464Search in Google Scholar

16. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 2007; 8:357-66.10.1111/j.1468-1293.2007.00477.x17661843Search in Google Scholar

17. Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr. 2003; 142:47-52.10.1067/mpd.2003.mpd033512520254Search in Google Scholar

18. Russell VD, Jourdain G, Shapiro D, Ngo-Giang-Huong N, Frenkel L, Britto P, et al. A phase II study of the incidence of nevirapine resistance mutations in HIVinfected Thai women receiving a single intrapartum dose of NVP followed by a postpartum tail of ZDV/ddI or ZDV/ddI/LPV/r: IMPAACT P1032. Presented at 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February, 2009 (Abstract 95aLB).Search in Google Scholar

19. de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, et al. British HIV Association and Children’s HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 2008; 9:452-502.10.1111/j.1468-1293.2008.00619.x18840151Search in Google Scholar

20. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998; 339:1409-14.10.1056/NEJM1998111233920019811915Search in Google Scholar

21. Gonzalez-Tome MI, Ramos Amador JT, Guillen S, Solis I, Fernandez-Ibieta M, Munoz E, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med. 2008; 9:868-74.10.1111/j.1468-1293.2008.00639.x18983478Search in Google Scholar

22. Hitti J, Andersen J, McComsey G, Liu T, Melvin A, Smith L, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol. 2007; 196:331 e1-7.10.1016/j.ajog.2006.11.03717403409Search in Google Scholar

23. Ramautarsing R, van der Lugt J, Phanuphak N, Gorowara M, Kerr S, Chuemchaitrakool A, et al. Standard dose generic lopinavir/ritonavir provides adequate lopinavir plasma levels during the 3rd trimester of pregnancy in Thai HIV-1 infected women. Presented at 11th Workshop on Clinical Pharmacology of HIV Therapy, Sorento, April, 2010 (Poster 9).Search in Google Scholar

24. Cressy T, Jourdain G, Rawangban B, Yathavisuthi P, Varadisai S, Kongpanichkul R, et al, and the PHPT-5 Study Team. Pharmacokinetics of lopinavir boosted with ritonavir initiated during the third trimester of pregnancy in HIV-1-infected Thai women. Presented at 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February, 2010 (Abstract 906).Search in Google Scholar